Silence Therapeutics PLC ADR Annual stock financials by MarketWatch. View the latest SLN financial statements, income statements and financial ratios.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Topline results for Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for third quarter of 2026 ...